查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2017053

伤口生物製剂市场：全球市场按产品类型、应用、最终用户和分销管道分類的预测 - 2026-2032 年

Wound Biologics Market by Product Type, Application, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，伤口生物製剂市场价值将达到 3.9182 亿美元，到 2026 年将成长至 4.5269 亿美元，到 2032 年将达到 9.9077 亿美元，复合年增长率为 14.17%。

主要市场统计数据
基准年 2025 3.9182亿美元
预计年份：2026年 4.5269亿美元
预测年份 2032 9.9077亿美元
复合年增长率 (%) 14.17%

一份全面的总结，说明了目前影响伤口生物製剂领域的技术驱动因素、临床重点和策略动机。

由于科学进步、治疗路径的改变以及医疗保健相关人员日益增长的商业性兴趣，伤口生物製剂领域正在迅速发展。本文概述了该领域的现状，阐明了关键治疗方法的分类，并论证了为何临床医生、医院系统和生命科学投资者现在必须对伤口生物製剂疗法给予策略关注。

技术创新、监管政策的明确性以及医疗服务体系的改革，是如何重塑伤口生物製剂领域的竞争格局和推广路径的？

随着科学创新、监管进步和医疗服务体系改革的融合，伤口生物製剂领域正经历变革性的转变。在产品层面，支架工程、精准生长因子配方和自体血小板衍生成分的改进正在提升治疗的特异性和便利性。这些技术进步与监管途径相辅相成，监管途径日益认可生物製剂相对于传统外用药物的独特风险获益比，从而在安全性和生产控制措施健全的情况下，为生物製剂的临床应用铺平了道路。

系统性评估近期关税措施对伤口生物製剂领域采购决策、供应链韧性和采购行为的影响。

2025年实施的关税上调对伤口生物製剂的采购、生产策略和采购惯例产生了显着的下游影响。对进口原料、成品和生物製药组件征收的关税增加了接收成本，促使製造商重新评估其组件采购，并凸显了近岸外包和供应链多元化的重要性。因此，契约製造和供应商被迫重新评估其成本会计模式和库存策略，以在不中断临床试验点供应的情况下维持获利能力。

将产品模式、临床适应症、医疗保健环境和分销管道与策略商业化机会联繫起来的详细細項分析。

详细的市场细分揭示了产品、应用、终端用户和分销管道等各个类别中清晰的价值来源、临床应用案例和商业化路径。按产品类型划分，治疗领域包括胶原蛋白、生长因子、血小板衍生成分和皮肤替代物。在胶原蛋白製剂中，牛、马源和猪源胶原蛋白的免疫抗原性和操作特性各不相同，这会影响临床医生的选择和监管策略。生长因子类别包括表皮生长因子、纤维母细胞生长因子、血小板衍生生长因子和血管内皮生长因子，每种生长因子都有独特的作用机制，指南适应症的选择和联合治疗。血小板衍生製剂，以浓缩血小板纤维蛋白和浓缩血小板血浆为代表，属于自体，其独特之处在于能够作为临床干预手段改变治疗过程。皮肤替代物包括生物真皮、复合真皮和合成真皮结构，反映了生物整合和生产一致性之间的权衡。

区域比较分析揭示了管理体制、支付方优先事项和医疗保健基础设施如何决定全球市场的采用路径。

区域趋势正在以不同的方式影响美洲、欧洲、中东和非洲以及亚太市场的技术采纳、报销政策和供应链策略。在美洲，完善的临床基础设施和成熟的创伤护理专业网路促进了新型生物製剂的早期应用，这些製剂展现出临床差异化优势和营运效率。此外，这些市场优先考虑透过真实世界研究和整合式护理路径来获取证据，从而催生了对能够展现以患者为中心的疗效的产品的需求。

评估竞争定位和策略性倡议，以推动创新通路、生产规模和证据产生能力的差异化。

伤口生物製剂领域的竞争格局由差异化的科学平台、生产能力和实证医学证据所构成。领先的技术开发商正投资于下一代支架化学、多因子生长因子组合和标准化自体组织处理系统，而契约製造和元件供应商则在不断提升自身能力，以满足生物製剂严格的品质和无菌要求。策略性措施还包括与临床专家和产品开发人员伙伴关係，共同设计符合实际临床工作流程的操作和应用方案。

为製造商和供应商制定具体和优先行动，以协调创新重点、加强供应链，并加速伤口生物製剂领域临床机构和保险公司的采用。

产业领导者应采取一系列协调一致的措施，在有效管理商业性和营运风险的同时，充分利用科学进步。首先，研发重点应与医疗机构的实际需求相契合，开发出符合医院、创伤护理中心、门诊手术中心和居家照护机构在处理、储存和应用方面实际要求的产品。其次，透过采购多元化、近岸外包以及策略性库存管理政策，增强供应链韧性，进而降低贸易政策波动和物流中断带来的风险。

透明的混合方法研究框架结合了对临床医生的访谈、对技术文件的审查以及供应链分析，检验了具有临床和商业性意义的研究结果。

本研究采用混合方法，结合一手定性访谈、二手文献综述、产品技术文件和供应链图谱，对伤口生物製剂领域进行了严谨而实用的分析。一手资讯包括对医院临床医生、创伤护理专家、采购经理、法规专家和生产合作伙伴的结构化访谈，旨在了解实际应用模式、未满足的临床需求和采购考量。这些观点与法规指南、同行评审的科学文献和产品标籤资讯进行交叉比对，以检验作用机制和安全性特征。

这项具有前瞻性的综合分析强调，涵盖研发、供应链和市场准入的整合策略对于在伤口生物製剂领域获得可持续的竞争优势至关重要。

总之，伤口生物製剂领域正处于一个转折点，科学进步、变革性护理模式和商业性压力在此交汇，既带来了机会，也带来了挑战。兼具强大生物功能、实用临床应用性和可靠供应的技术将很快被采用。同时，不断变化的贸易政策和报销预期要求製造商在产品生产地点和方式、定价以及证据呈现等方面采取策略性方法。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 伤口生物製剂市场：依产品类型划分

  • 胶原蛋白
    • 牛胶原蛋白
    • 马胶原胶原蛋白
    • 猪胶原胶原蛋白
  • 生长因子
    • 表皮生长因子
    • 纤维母细胞生长因子
    • 血小板衍生生长因子
    • 血管内皮生长因子
  • 血小板衍生製剂
    • 血小板浓缩纤维蛋白
    • 富血小板血浆
  • 皮肤替代材料
    • 活体真皮
    • 复合真皮
    • 合成真皮

第九章 伤口生物製剂市场：依应用领域划分

  • 急性伤口
  • 烧伤
    • 二度烧伤
    • 三度烧伤
  • 慢性伤口
    • 糖尿病足溃疡
    • 压疮
    • 下肢静脉溃疡
  • 手术伤口

第十章 伤口生物製剂市场：依最终使用者划分

  • 门诊手术中心
  • 居家照护
  • 医院
  • 创伤护理中心

第十一章 伤口生物製剂市场：依通路划分

  • 离线
  • 在线的

第十二章 伤口生物製剂市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 伤口生物製剂市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 伤口生物製剂市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国伤口生物製剂市场

第十六章：中国伤口生物製剂市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • 3M Company
  • Alliqua BioMedical, Inc.
  • Avita Medical Ltd.
  • Celularity, Inc.
  • CollPlant Biotechnologies Ltd.
  • Integra LifeSciences Holdings Corporation
  • MiMedx Group, Inc.
  • Molnlycke Health Care AB
  • Organogenesis Inc.
  • Smith & Nephew plc
Product Code: MRR-0315DDADCE4B

The Wound Biologics Market was valued at USD 391.82 million in 2025 and is projected to grow to USD 452.69 million in 2026, with a CAGR of 14.17%, reaching USD 990.77 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 391.82 million
Estimated Year [2026] USD 452.69 million
Forecast Year [2032] USD 990.77 million
CAGR (%) 14.17%

A comprehensive orienting summary that explains current technological drivers, clinical priorities, and strategic motivations shaping the wound biologics sector

The wound biologics landscape is rapidly evolving, driven by scientific progress, changing care pathways, and heightened commercial interest across healthcare stakeholders. This introduction distills the field's contemporary contours, clarifies the principal classes of therapeutic modalities, and frames why strategic attention to biologic wound therapies is now imperative for clinicians, hospital systems, and life sciences investors.

Recent advances in biomaterials, regenerative medicine, and point-of-care delivery have shifted wound care from purely symptomatic management to targeted biological intervention. As a result, clinicians seek products that integrate scaffold performance, growth factor activity, and autologous preparations with clear handling and safety profiles. Meanwhile, health systems and ambulatory providers are recalibrating procurement and care pathways to prioritize therapies that reduce complications, shorten healing times, and optimize resource utilization. This introduction sets the context for the subsequent sections by outlining key technological trajectories, reimbursement considerations, and cross-stakeholder expectations that together shape near-term commercial and clinical decision-making.

How converging technical innovations, regulatory clarity, and care delivery reforms are reshaping competitive dynamics and adoption pathways across wound biologics

The wound biologics sector is experiencing transformative shifts that recombine scientific innovation, regulatory evolution, and care delivery reforms. At the product level, improvements in scaffold engineering, precision growth factor formulations, and autologous platelet derivatives are enhancing therapeutic specificity and usability. These technological advances are complemented by regulatory pathways that increasingly recognize the distinct risk-benefit profiles of biologics versus traditional topical agents, allowing clearer pathways to clinical adoption when safety and manufacturing controls are robust.

Concurrently, delivery models are changing: hospitals and wound care centers are integrating biologic therapies earlier in care algorithms, while ambulatory surgical centers and home care providers are adopting streamlined products designed for lower-complexity settings. Payment models and value-based contracting are nudging manufacturers to demonstrate real-world effectiveness and predictable outcomes. Taken together, these shifts create a more competitive environment in which clinical differentiation, supply chain resilience, and evidence generation are decisive. Strategic alignment across R&D, regulatory affairs, and commercial functions will determine which organizations capitalize on these structural changes.

Evaluating the systemic consequences of recent tariff actions on sourcing decisions, supply chain resilience, and procurement behaviors within wound biologics

The introduction of elevated tariff measures in 2025 has created material downstream effects across sourcing, manufacturing strategy, and procurement practices for wound biologics. Tariffs applied to imported raw materials, finished devices, and biologic components have increased landed costs and prompted manufacturers to reassess component sourcing, with a renewed emphasis on nearshoring and supply base diversification. In turn, contract manufacturers and suppliers have needed to revisit costing models and inventory strategies to preserve margins while ensuring uninterrupted supply to clinical customers.

These trade policy shifts have also influenced clinical adoption patterns indirectly. Procurement teams within hospitals and wound care centers are placing greater weight on total cost of ownership and supply certainty when evaluating supplier partnerships; products that offer simplified handling and reduced dependence on imported ancillary materials gain a comparative advantage. Further, some innovators are accelerating localized manufacturing investments and technology transfers to mitigate tariff exposure and shorten lead times. Overall, the 2025 tariff environment has elevated supply chain strategy to a core commercial imperative, making resilience, flexibility, and cost transparency critical for sustained market participation.

A granular segmentation analysis linking product modalities, clinical indications, care settings, and distribution channels to strategic commercialization opportunities

Detailed segmentation illuminates distinct value drivers, clinical use cases, and commercial pathways across product, application, end user, and distribution channel categories. Based on product type, the therapeutic set includes Collagen, Growth Factors, Platelet Derivatives, and Skin Substitutes; within Collagen formulations, bovine, equine, and porcine sources present differing immunogenic and handling profiles that affect clinician preference and regulatory strategy. The Growth Factors category encompasses epidermal growth factor, fibroblast growth factor, platelet-derived growth factor, and vascular endothelial growth factor, each with unique mechanisms that guide indication targeting and combination approaches. Platelet Derivatives are represented by platelet-rich fibrin and platelet-rich plasma, which are distinctive for being autologous, point-of-care interventions that shift procedural workflows. Skin Substitutes include biological dermal, composite dermal, and synthetic dermal constructs, with trade-offs between biological integration and manufacturing consistency.

Turning to application-based segmentation, acute wounds, burns, chronic wounds, and surgical wounds define different clinical endpoints and evidence expectations; burns subdivide into second-degree and third-degree presentations while chronic wounds include diabetic foot ulcers, pressure ulcers, and venous leg ulcers, each requiring tailored therapeutic strategies. End-user segmentation spans ambulatory surgical centers, home care, hospitals, and wound care centers, a mix that underscores varying procurement cycles, clinician competencies, and procedural settings. Finally, distribution channels are broadly offline and online, the former encompassing traditional clinical distributors and hospital supply chains and the latter growing through direct-to-provider and institutional e-commerce platforms. Integrating these segment dimensions reveals where clinical need, operational feasibility, and commercial scale align to favor specific technologies and go-to-market approaches.

Comparative regional intelligence revealing how regulatory regimes, payer priorities, and care infrastructure determine pathways to adoption across global markets

Regional dynamics shape technology adoption, reimbursement policy, and supply chain strategy in distinct ways across the Americas, Europe, Middle East & Africa, and Asia-Pacific markets. In the Americas, strong clinical infrastructure and established wound care specialty networks favor early adoption of novel biologics that demonstrate clinical differentiation and operational efficiency. These markets also prioritize evidence generation through real-world studies and integrated care pathways, creating demand for products that can show patient-centric outcomes.

In Europe, Middle East & Africa, heterogeneous regulatory regimes and payer systems require localized market access strategies, with some territories emphasizing cost-effectiveness and centralized procurement and others relying on specialist centers to champion innovations. The Asia-Pacific region exhibits rapid expansion in clinical capacity and manufacturing investment, fostering both demand and the potential for regional production scale. Across these geographies, differences in clinician training, reimbursement levers, and supply chain infrastructure mean that manufacturers must adopt region-specific evidence plans, distribution partnerships, and regulatory strategies to realize adoption at scale.

An assessment of competitive positioning and strategic moves that drive differentiation across innovation pipelines, manufacturing scale, and evidence-generation capabilities

Competitive dynamics within wound biologics are defined by differentiated science platforms, manufacturing capabilities, and evidence portfolios. Leading technology developers are investing in next-generation scaffold chemistries, multi-factor growth factor combinations, and standardized autologous processing systems, while contract manufacturers and component suppliers are scaling capabilities to meet stringent biologics quality and sterility demands. Strategic activity also includes partnerships between clinical leaders and product developers to co-design handling and application protocols that align with real-world workflows.

Moreover, go-to-market differentiation increasingly hinges on post-marketing data capture, real-world evidence generation, and health economic modeling that speak to payers and hospital purchasing. Some companies are prioritizing vertically integrated approaches to control supply chain risks, while others are forming alliances to expand distribution reach into ambulatory and home care channels. As market maturity advances, expect consolidation around integrated platforms that combine robust clinical outcomes with scalable manufacturing and reliable distribution footprints, thereby setting a higher bar for new entrants.

Concrete, prioritized actions for manufacturers and providers to align innovation priorities, fortify supply chains, and accelerate clinical and payer adoption in wound biologics

Industry leaders should adopt a coordinated set of actions to capitalize on scientific advances while managing commercial and operational risks. First, align R&D prioritization with care setting needs by developing products that meet the handling, storage, and application realities of hospitals, wound care centers, ambulatory surgical centers, and home care providers. Second, enhance supply chain resilience through diversified sourcing, nearshoring options, and strategic inventory policies that mitigate exposure to trade policy shifts and logistical disruptions.

Third, invest in rigorous clinical and health economic evidence that addresses payer concerns and facilitates pathway adoption; pragmatic trials and real-world registries can accelerate reimbursement conversations. Fourth, tailor regional market access plans that reflect local regulatory frameworks and procurement dynamics, ensuring that market entry sequences are optimized for reimbursement and clinician engagement. Finally, explore partnership models that bundle products with training, digital tracking, and outcome measurement to create differentiated value propositions that capture both clinical and economic stakeholders.

A transparent mixed-methods research framework combining clinician interviews, technical dossier review, and supply chain analysis to validate clinically and commercially relevant findings

This research synthesis draws on a mixed-methods approach that integrates primary qualitative interviews, secondary literature review, product technical dossiers, and supply chain mapping to construct a rigorous and actionable view of the wound biologics sector. Primary inputs include structured interviews with clinicians across hospital settings, wound care specialists, procurement leaders, regulatory experts, and manufacturing partners to capture real-world usage patterns, unmet clinical needs, and sourcing considerations. These perspectives were triangulated with regulatory guidance, peer-reviewed scientific literature, and product labeling information to validate mechanism-of-action claims and safety profiles.

In addition, supply chain analyses employed trade flow data, component sourcing reviews, and contract manufacturing assessments to illuminate tariff exposure and manufacturing risk. Segmentation frameworks were populated by mapping product characteristics to clinical indications and end-user workflows, and distribution channel analysis evaluated transactional friction points and digital adoption trends. Throughout, findings were cross-validated through iterative stakeholder feedback to ensure relevance and practical applicability for commercial and clinical decision-makers.

A forward-looking synthesis emphasizing the imperative for integrated strategies across R&D, supply chain, and market access to secure durable advantage in wound biologics

In conclusion, the wound biologics field stands at an inflection point where scientific progress, shifting care models, and commercial pressures converge to create both opportunity and complexity. Technologies that marry robust biological function with practical clinical handling and supply reliability will win early adoption. Concurrently, changes in trade policy and reimbursement expectations mean that manufacturers must be strategic about where and how they produce, price, and evidence their products.

Looking forward, organizations that integrate cross-functional planning-from R&D and regulatory to supply chain and market access-will be best positioned to capture durable value. Success will depend on demonstrating real-world outcomes, maintaining manufacturing and distribution resilience, and executing regionally nuanced commercialization strategies that reflect distinct payer and clinical landscapes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Wound Biologics Market, by Product Type

  • 8.1. Collagen
    • 8.1.1. Bovine Collagen
    • 8.1.2. Equine Collagen
    • 8.1.3. Porcine Collagen
  • 8.2. Growth Factors
    • 8.2.1. Epidermal Growth Factor
    • 8.2.2. Fibroblast Growth Factor
    • 8.2.3. Platelet Derived Growth Factor
    • 8.2.4. Vascular Endothelial Growth Factor
  • 8.3. Platelet Derivatives
    • 8.3.1. Platelet Rich Fibrin
    • 8.3.2. Platelet Rich Plasma
  • 8.4. Skin Substitutes
    • 8.4.1. Biological Dermal
    • 8.4.2. Composite Dermal
    • 8.4.3. Synthetic Dermal

9. Wound Biologics Market, by Application

  • 9.1. Acute Wounds
  • 9.2. Burns
    • 9.2.1. Second Degree Burns
    • 9.2.2. Third Degree Burns
  • 9.3. Chronic Wounds
    • 9.3.1. Diabetic Foot Ulcer
    • 9.3.2. Pressure Ulcer
    • 9.3.3. Venous Leg Ulcer
  • 9.4. Surgical Wounds

10. Wound Biologics Market, by End User

  • 10.1. Ambulatory Surgical Centers
  • 10.2. Home Care
  • 10.3. Hospitals
  • 10.4. Wound Care Centers

11. Wound Biologics Market, by Distribution Channel

  • 11.1. Offline
  • 11.2. Online

12. Wound Biologics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Wound Biologics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Wound Biologics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Wound Biologics Market

16. China Wound Biologics Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. 3M Company
  • 17.6. Alliqua BioMedical, Inc.
  • 17.7. Avita Medical Ltd.
  • 17.8. Celularity, Inc.
  • 17.9. CollPlant Biotechnologies Ltd.
  • 17.10. Integra LifeSciences Holdings Corporation
  • 17.11. MiMedx Group, Inc.
  • 17.12. Molnlycke Health Care AB
  • 17.13. Organogenesis Inc.
  • 17.14. Smith & Nephew plc

LIST OF FIGURES

  • FIGURE 1. GLOBAL WOUND BIOLOGICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL WOUND BIOLOGICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL WOUND BIOLOGICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES WOUND BIOLOGICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA WOUND BIOLOGICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL WOUND BIOLOGICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY COLLAGEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY COLLAGEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY COLLAGEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY COLLAGEN, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY BOVINE COLLAGEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY BOVINE COLLAGEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY BOVINE COLLAGEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY EQUINE COLLAGEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY EQUINE COLLAGEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY EQUINE COLLAGEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY PORCINE COLLAGEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY PORCINE COLLAGEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY PORCINE COLLAGEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY EPIDERMAL GROWTH FACTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY EPIDERMAL GROWTH FACTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY EPIDERMAL GROWTH FACTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY FIBROBLAST GROWTH FACTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY FIBROBLAST GROWTH FACTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY FIBROBLAST GROWTH FACTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVED GROWTH FACTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVED GROWTH FACTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVED GROWTH FACTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY VASCULAR ENDOTHELIAL GROWTH FACTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY VASCULAR ENDOTHELIAL GROWTH FACTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY VASCULAR ENDOTHELIAL GROWTH FACTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVATIVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVATIVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVATIVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY PLATELET RICH FIBRIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY PLATELET RICH FIBRIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY PLATELET RICH FIBRIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY PLATELET RICH PLASMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY PLATELET RICH PLASMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY PLATELET RICH PLASMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY BIOLOGICAL DERMAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY BIOLOGICAL DERMAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY BIOLOGICAL DERMAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY COMPOSITE DERMAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY COMPOSITE DERMAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY COMPOSITE DERMAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY SYNTHETIC DERMAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY SYNTHETIC DERMAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY SYNTHETIC DERMAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY ACUTE WOUNDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY ACUTE WOUNDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY ACUTE WOUNDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY BURNS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY BURNS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY BURNS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY BURNS, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY SECOND DEGREE BURNS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY SECOND DEGREE BURNS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY SECOND DEGREE BURNS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY THIRD DEGREE BURNS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY THIRD DEGREE BURNS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY THIRD DEGREE BURNS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY DIABETIC FOOT ULCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY DIABETIC FOOT ULCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY DIABETIC FOOT ULCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY PRESSURE ULCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY PRESSURE ULCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY PRESSURE ULCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY VENOUS LEG ULCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY VENOUS LEG ULCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY VENOUS LEG ULCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY SURGICAL WOUNDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY SURGICAL WOUNDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY SURGICAL WOUNDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY WOUND CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY WOUND CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY WOUND CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS WOUND BIOLOGICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS WOUND BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS WOUND BIOLOGICS MARKET SIZE, BY COLLAGEN, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS WOUND BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS WOUND BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS WOUND BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS WOUND BIOLOGICS MARKET SIZE, BY BURNS, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS WOUND BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS WOUND BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS WOUND BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA WOUND BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA WOUND BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA WOUND BIOLOGICS MARKET SIZE, BY COLLAGEN, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA WOUND BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA WOUND BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA WOUND BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA WOUND BIOLOGICS MARKET SIZE, BY BURNS, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA WOUND BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA WOUND BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA WOUND BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA WOUND BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA WOUND BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA WOUND BIOLOGICS MARKET SIZE, BY COLLAGEN, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA WOUND BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA WOUND BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA WOUND BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA WOUND BIOLOGICS MARKET SIZE, BY BURNS, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA WOUND BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA WOUND BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA WOUND BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA WOUND BIOLOGICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA WOUND BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA WOUND BIOLOGICS MARKET SIZE, BY COLLAGEN, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA WOUND BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA WOUND BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA WOUND BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA WOUND BIOLOGICS MARKET SIZE, BY BURNS, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA WOUND BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA WOUND BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA WOUND BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE WOUND BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE WOUND BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE WOUND BIOLOGICS MARKET SIZE, BY COLLAGEN, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE WOUND BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE WOUND BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE WOUND BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE WOUND BIOLOGICS MARKET SIZE, BY BURNS, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE WOUND BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE WOUND BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE WOUND BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST WOUND BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST WOUND BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST WOUND BIOLOGICS MARKET SIZE, BY COLLAGEN, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST WOUND BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 166. MIDDLE EAST WOUND BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST WOUND BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST WOUND BIOLOGICS MARKET SIZE, BY BURNS, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST WOUND BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST WOUND BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST WOUND BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA WOUND BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA WOUND BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA WOUND BIOLOGICS MARKET SIZE, BY COLLAGEN, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA WOUND BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA WOUND BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA WOUND BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA WOUND BIOLOGICS MARKET SIZE, BY BURNS, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA WOUND BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA WOUND BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA WOUND BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC WOUND BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC WOUND BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC WOUND BIOLOGICS MARKET SIZE, BY COLLAGEN, 2018-2032 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC WOUND BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC WOUND BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC WOUND BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC WOUND BIOLOGICS MARKET SIZE, BY BURNS, 2018-2032 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC WOUND BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, 2018-2032 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC WOUND BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC WOUND BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN WOUND BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. ASEAN WOUND BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. ASEAN WOUND BIOLOGICS MARKET SIZE, BY COLLAGEN, 2018-2032 (USD MILLION)
  • TABLE 198. ASEAN WOUND BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 199. ASEAN WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 200. ASEAN WOUND BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 201. ASEAN WOUND BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 202. ASEAN WOUND BIOLOGICS MARKET SIZE, BY BURNS, 2018-2032 (USD MILLION)
  • TABLE 203. ASEAN WOUND BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, 2018-2032 (USD MILLION)
  • TABLE 204. ASEAN WOUND BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 205. ASEAN WOUND BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 206. GCC WOUND BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 207. GCC WOUND BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. GCC WOUND BIOLOGICS MARKET SIZE, BY COLLAGEN, 2018-2032 (USD MILLION)
  • TABLE 209. GCC WOUND BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 210. GCC WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 211. GCC WOUND BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 212. GCC WOUND BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 213. GCC WOUND BIOLOGICS MARKET SIZE, BY BURNS, 2018-2032 (USD MILLION)
  • TABLE 214. GCC WOUND BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, 2018-2032 (USD MILLION)
  • TABLE 215. GCC WOUND BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. GCC WOUND BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPEAN UNION WOUND BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPEAN UNION WOUND BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPEAN UNION WOUND BIOLOGICS MARKET SIZE, BY COLLAGEN, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPEAN UNION WOUND BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPEAN UNION WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPEAN UNION WOUND BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPEAN UNION WOUND BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPEAN UNION WOUND BIOLOGICS MARKET SIZE, BY BURNS, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPEAN UNION WOUND BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPEAN UNION WOUND BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPEAN UNION WOUND BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 228. BRICS WOUND BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 229. BRICS WOUND BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. BRICS WOUND BIOLOGICS MARKET SIZE, BY COLLAGEN, 2018-2032 (USD MILLION)
  • TABLE 231. BRICS WOUND BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 232. BRICS WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 233. BRICS WOUND BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 234. BRICS WOUND BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 235. BRICS WOUND BIOLOGICS MARKET SIZE, BY BURNS, 2018-2032 (USD MILLION)
  • TABLE 236. BRICS WOUND BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, 2018-2032 (USD MILLION)
  • TABLE 237. BRICS WOUND BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 238. BRICS WOUND BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 239. G7 WOUND BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 240. G7 WOUND BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. G7 WOUND BIOLOGICS MARKET SIZE, BY COLLAGEN, 2018-2032 (USD MILLION)
  • TABLE 242. G7 WOUND BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 243. G7 WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 244. G7 WOUND BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 245. G7 WOUND BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 246. G7 WOUND BIOLOGICS MARKET SIZE, BY BURNS, 2018-2032 (USD MILLION)
  • TABLE 247. G7 WOUND BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, 2018-2032 (USD MILLION)
  • TABLE 248. G7 WOUND BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 249. G7 WOUND BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 250. NATO WOUND BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 251. NATO WOUND BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. NATO WOUND BIOLOGICS MARKET SIZE, BY COLLAGEN, 2018-2032 (USD MILLION)
  • TABLE 253. NATO WOUND BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 254. NATO WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 255. NATO WOUND BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 256. NATO WOUND BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 257. NATO WOUND BIOLOGICS MARKET SIZE, BY BURNS, 2018-2032 (USD MILLION)
  • TABLE 258. NATO WOUND BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, 2018-2032 (USD MILLION)
  • TABLE 259. NATO WOUND BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 260. NATO WOUND BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 261. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 262. UNITED STATES WOUND BIOLOGICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 263. UNITED STATES WOUND BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 264. UNITED STATES WOUND BIOLOGICS MARKET SIZE, BY COLLAGEN, 2018-2032 (USD MILLION)
  • TABLE 265. UNITED STATES WOUND BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 266. UNITED STATES WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 267. UNITED STATES WOUND BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 268. UNITED STATES WOUND BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 269. UNITED STATES WOUND BIOLOGICS MARKET SIZE, BY BURNS, 2018-2032 (USD MILLION)
  • TABLE 270. UNITED STATES WOUND BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, 2018-2032 (USD MILLION)
  • TABLE 271. UNITED STATES WOUND BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 272. UNITED STATES WOUND BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 273. CHINA WOUND BIOLOGICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 274. CHINA WOUND BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 275. CHINA WOUND BIOLOGICS MARKET SIZE, BY COLLAGEN, 2018-2032 (USD MILLION)
  • TABLE 276. CHINA WOUND BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 277. CHINA WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 278. CHINA WOUND BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 279. CHINA WOUND BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 280. CHINA WOUND BIOLOGICS MARKET SIZE, BY BURNS, 2018-2032 (USD MILLION)
  • TABLE 281. CHINA WOUND BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, 2018-2032 (USD MILLION)
  • TABLE 282. CHINA WOUND BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 283. CHINA WOUND BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)